Pharmaceutical chemistry Content

Researchers Step Closer to Mimicking Nature’s Mastery of Chemistry

Andy Fell — January 10, 2024 - 8:45am

In nature, organic molecules are either left- or right-handed, but synthesizing molecules with a specific “handedness” in a lab is hard to do. Make a drug or enzyme with the wrong “handedness,” and it just won’t work. Now chemists at the ��Ƶ, Davis, are getting closer to mimicking nature’s chemical efficiency through computational modeling and physical experimentation.

��Ƶ Establishes Institute for Psychedelics and Neurotherapeutics

Andy Fell — February 02, 2023 - 5:00am

The ��Ƶ, Davis, has launched the Institute for Psychedelics and Neurotherapeutics to advance basic knowledge about the mechanisms of psychedelics and translate it into safe and effective treatments for diseases such as depression, post-traumatic stress disorder, addiction, Alzheimer’s disease and Parkinson’s disease, among others.

PsychLight Sensor to Enable Discovery of New Psychiatric Drugs

Andy Fell — April 28, 2021 - 8:30am

Introducing psychLight: a sensor for mental illness treatment and drug abuse detection. Learn how ��Ƶ researchers are advancing mental health technology.

New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression

Andy Fell — December 09, 2020 - 8:08am

A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the ��Ƶ, Davis. A paper describing the work is published Dec. 9 in Nature.

“Psychedelics are some of the most powerful drugs we know of that affect the brain,” said David Olson, assistant professor of chemistry at ��Ƶ and senior author on the paper. “It’s unbelievable how little we know about them.”

Pharmaceutical chemistry Content

Researchers Step Closer to Mimicking Nature’s Mastery of Chemistry

������Ƶ Establishes Institute for Psychedelics and Neurotherapeutics

PsychLight Sensor to Enable Discovery of New Psychiatric Drugs

New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression

��Ƶ Establishes Institute for Psychedelics and Neurotherapeutics